Solubilizate with curcumin and boswellia and xanthohumol

Abstract

A solubilizate comprises curcumin in a content of less than or equal to 10 wt %, preferably less than or equal to 8 wt %, most preferably 3 wt % to 7 wt %, one or more boswellia acids and/or one or more boswellia acid derivatives in a total content of less than or equal to 10 wt %, preferably less than or equal to 8 wt %, most preferably 4.7 wt % to 6.6 wt %, xanthohumol in a content of less than or equal to 10 wt %, preferably less than or equal to 5 wt %, most preferably 1 wt % to 3 wt %, and at least one emulsifier with an HLB value in a range of less than 18, preferably between 13 and 18, in particular polysorbate 80 or polysorbate 20 or a mixture of polysorbate 20 and polysorbate 80.

What is claimed is: 
     
         1 . A method for preventing and/or treating diseases involving inflammation and/or metabolic syndrome in a patient, comprising
 administering an effective amount of a solubilizate, the solubilizate comprising:
 3 wt % to 10 wt % curcumin; 
 3 wt % to 10 wt % of one or more boswellic acids and/or one or more boswellic acid derivatives; 
 1 wt % to 10 wt % xanthohumol; and 
 at least one emulsifier, namely polysorbate 80 or polysorbate 20 or a mixture of polysorbate 20 and polysorbate 80, 
 wherein the emulsifier content is at least 70 wt %. 
   
     
     
         2 . The method according to  claim 1 ,
 wherein the solubilizate comprises 3 wt % to 8 wt % curcumin.   
     
     
         3 . The method according to  claim 1 ,
 wherein the solubilizate comprises 3 wt % to 7 wt % curcumin.   
     
     
         4 . The method according to  claim 1 ,
 wherein the one or more boswellic acids and/or one or more boswellic acid derivatives comprise one or more of 11 keto-β-boswellic acid, KBA, (CAS 17019-92-0), 3-O-acetyl-11-keto-β-boswellic acid, AKBA, (CAS 67416-16-9), 3-O-acetyl-α-boswellic acid, AαBA, and 3-O-acetyl-β-boswellic acid, AβBA.   
     
     
         5 . The method according to  claim 1 ,
 wherein the solubilizate comprises 3 wt % to 8 wt % of the one or more boswellic acids and/or one or more boswellic acid derivatives.   
     
     
         6 . The method according to  claim 1 ,
 wherein the solubilizate comprises 3 wt % to 6.6 wt % of the one or more boswellic acids and/or one or more boswellic acid derivatives.   
     
     
         7 . The method according to  claim 1 ,
 wherein the solubilizate comprises 1 wt % to 5 wt % xanthohumol.   
     
     
         8 . The method according to  claim 1 ,
 wherein the solubilizate comprises 1 wt % to 3 wt % xanthohumol.   
     
     
         9 . The method according to  claim 1 ,
 wherein the emulsifier content is in a range between 75 wt % and 95 wt %.   
     
     
         10 . The method according to  claim 1 ,
 wherein the emulsifier content is in a range between 79 wt % and 88 wt %.   
     
     
         11 . The method according to  claim 1 ,
 wherein the solubilizate contains an extract from a resin of a  boswellia serrata  plant obtained by extraction with ethyl acetate, as a source for the one or more boswellic acids and/or one or more boswellic acid derivatives, wherein this extract contains boswellic acids in a concentration of at least 85 wt %.   
     
     
         12 . The method according to  claim 1 ,
 wherein, within the solubilizate, a ratio of emulsifier to boswellic acids and/or to boswellic acids and at least one of their derivatives is in a range between 20:1 and 3:1.   
     
     
         13 . The method according to  claim 1 ,
 wherein, within the solubilizate, a ratio of emulsifier to curcumin is in a range between 30:1 and 3:1.   
     
     
         14 . The method according to  claim 1 ,
 wherein, within the solubilizate, a ratio of emulsifier to xanthohumol is in a range between 30:1 and 3:1.   
     
     
         15 . The method according to  claim 1 ,
 wherein the solubilizate contains up to 20 wt % of ethanol.   
     
     
         16 . The method according to  claim 1 ,
 wherein a diameter distribution of micelles in a dilution of the solubilizate with distilled water in a ratio of 1:500 at pH 1.1 and 37° C. is in a range from d 10 =6 nm to d 90 =16 nm.   
     
     
         17 . The method according to  claim 1 ,
 wherein the solubilizate exhibits a turbidity of less than 25 FNU, measured by scattered light measurement using infrared light according to the specifications of the ISO 7027 standard at a dilution of the solubilizate in a ratio of 1:50 in water under physiological conditions (pH 1.1 and 37° C.).   
     
     
         18 . The method according to  claim 1 ,
 wherein the solubilizate contains the xanthohumol in non-solubilized form.   
     
     
         19 . The method according to  claim 1 ,
 wherein the solubilizate is administered in a capsule.   
     
     
         20 . The method according to  claim 1 ,
 wherein the solubilizate is administered in an aqueous dilution.